Thu, Mar 5, 2015, 12:16 AM EST - U.S. Markets open in 9 hrs 14 mins

Recent

% | $
Quotes you view appear here for quick access.

BIOLASE, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • simonig simonig Oct 8, 2012 11:50 AM Flag

    BIOL's New Epic 10 Soft Tissue Lasser Will Dramatically Improve Revenue Results Starting In Q4 Period

    The BIOL patent protected technology is a paradigm shift for the dental industry and general surgery. Their unique technology allows for Bloodless and painless dental work and surgery. This is a tremendous advance. BIOL has the products on the market now. The table is set.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • They have had all this for years! Still have not been able to be profitable. At $6000 a unit they will have to sell a huge number to create a meaningful bump in revenue. Good Luck but don't expect a dramatic change soon of ever.

      • 2 Replies to mississippijohnhurt1
      • Hi John,
        The Waterlase i-Plus is the product that addressed the complaints of the dental community and made the i-Plus as fast as the high speed drill. The i-Plus has been on the market for less than two years. During the last two years the Henry Schein agreement stood in the way of increasing sales. They terminated that agreement for good only this past April. It is only now that the way is clear for increasing sales. Thank you for the "good luck" but this company has been revamped and has been put on a solid footing. They now have the products and the logjam of the Henry Schein agreement is gone. IMHO the table is set.

        Best Regards,

        Simon

        Sentiment: Strong Buy

      • i agree...the epic 10 is a cheaper ez-laze....so instead of $10,0000 a unit they will take $5,0000

 
BIOL
1.95-0.15(-7.14%)Mar 4 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.